Abstract:Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive decline in multiple cognitive domains and it becomes the most common cause of dementia in the elderly. There is an urgent need for the early diagnosis and treatment of AD to ease caregiver burden and medical costs, as well as improve patients' living activities associated with the dramatic increasing number of affected individuals. Molecular imaging with target-specific probes is contributing to identify the underlying biology in AD, which benefits to the early diagnosis of AD and the evaluation of anti-AD therapy. Molecular imaging probes, such as C-11-PIB, C-11-MP4A, F-18-AV-45, and F-18-FDG, can selectively bind to special bimolecular of AD or accurately accumulate at the location of damage areas, thus become an edge tool for a better management of the diseases in the clinical practice and new drug development. In the past decades, a large variety of probes is being developed and tested to be useful for the early and accurate diagnosis of Alzheimer's disease, patient selection for disease-modifying therapeutic trials and monitoring the effect of anti-amyloid therapy. Since imaging probes may also help to guide physicians to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug, this paper is to present a perspective of the available imaging probes for AD, classified on different modalities. Meanwhile, recent advances of those probes that have been selected for clinical trials and are at the different stages of the US Food and Drugs Administration (FDA) approval are outlined. Additionally, future directions and specific application of imaging strategies designed for both diagnosis and treatment for AD are discussed.

PET/MR Imaging: New Frontier in Alzheimer's Disease and Other Dementias

PET/MR Imaging: New Frontier in Alzheimer's Disease and Other Dementias.

Integrated Positron Emission Tomography/Magnetic Resonance Imaging in Clinical Diagnosis of Alzheimer’s Disease

PET and MRI Imaging in Alzheimer’s Disease：Potential Mechanisms and Findings

PET molecular imaging for pathophysiological visualization in Alzheimer's disease

Progress of Alzheimer′s Disease Research Based on PET Imaging

Current status of PET tracers for the early diagnosis of Alzheimer's disease

PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research

International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease

Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future

Alzheimer's Disease: Potential Pathogenesis and Imaging Findings

Novel PET molecular probes for early diagnosis of Alzheimer's disease

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

Molecular Imaging of Alzheimer Disease

Advances in MRI in diagnosis of early-stage Alzheimer’sdisease

PET Imaging for Early Detection of Alzheimer’s Disease : From Pathologic to Physiologic Biomarkers

Novel brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease and mild cognitive impairment

PET imaging of neural activity, -amyloid, and tau in normal brain aging

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment

Advances in Diagnosing Mild Cognitive Impairment and Alzheimer’s Disease Using 11C-PIB- PET/CT and Common Neuropsychological Tests

Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies